What is the typical anemia type in adults with chronic kidney disease (CKD) and how should it be diagnosed and managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 21, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Anemia Type in Chronic Kidney Disease

The anemia of CKD is normocytic normochromic anemia, primarily caused by inadequate erythropoietin production from failing kidneys, with iron deficiency (both absolute and functional) as a major contributing factor. 1, 2, 3

Pathophysiology and Classification

The anemia develops through multiple mechanisms that distinguish it from other anemia types:

Primary Mechanism

  • Erythropoietin deficiency is the dominant cause, as diseased kidneys fail to produce adequate EPO in response to hypoxia 4, 3, 5
  • This results in normocytic normochromic red blood cells with inadequate bone marrow stimulation 2, 3

Iron Deficiency Component

CKD patients develop two distinct types of iron deficiency that complicate the anemia 1:

Absolute Iron Deficiency:

  • Transferrin saturation ≤20% with ferritin ≤100 μg/L (predialysis/peritoneal dialysis patients) 1, 6
  • Transferrin saturation ≤20% with ferritin ≤200 μg/L (hemodialysis patients) 1, 6

Functional Iron Deficiency:

  • Transferrin saturation ≤20% with elevated ferritin levels (>100-200 μg/L depending on dialysis status) 1
  • Iron stores are adequate but unavailable for erythropoiesis due to hepcidin-mediated sequestration 1
  • This represents kinetic iron deficiency where demand exceeds supply during erythropoiesis 1

Additional Contributing Factors

  • Shortened red blood cell survival and direct bone marrow suppression 1, 3
  • Chronic inflammation causing hepcidin elevation and iron sequestration 1, 3
  • Blood loss from dialysis, phlebotomy, or GI sources 1
  • Reduced iron absorption from the gut due to elevated hepcidin 1

Diagnostic Approach

When to Screen

  • All CKD patients should undergo hemoglobin testing regardless of stage or cause 1
  • Screen at least annually, with more frequent monitoring for diabetic patients 7
  • Anemia prevalence increases dramatically when GFR <60 mL/min/1.73m² (Stage 3) and is nearly universal at Stage 5 1

Diagnostic Thresholds

Define anemia at these hemoglobin levels 1:

  • <13.5 g/dL in adult males
  • <12.0 g/dL in adult females

Essential Laboratory Workup

When anemia is identified, obtain 7:

  • Complete blood count with reticulocyte count to assess bone marrow response
  • Iron studies: serum ferritin and transferrin saturation
  • Stool guaiac when iron deficiency is detected
  • Vitamin B12 and folate if macrocytosis present
  • C-reactive protein to evaluate inflammation when ferritin is elevated

Critical Interpretation Caveat

Ferritin is an acute-phase reactant and may be falsely elevated in inflammation despite true iron deficiency 1, 7. In inflammatory states, transferrin saturation becomes more reliable than ferritin alone 7. The diagnostic thresholds for iron deficiency in CKD differ substantially from the general population due to this complexity 1.

Management Implications

The normocytic normochromic nature with multifactorial etiology requires:

  • Iron supplementation (IV preferred for dialysis patients) before or concurrent with ESA therapy 1, 8, 6
  • Erythropoiesis-stimulating agents once hemoglobin falls below 9-10 g/dL 8
  • Target hemoglobin 9-11.5 g/dL (never exceed 13 g/dL due to increased mortality risk) 8
  • Exclude other causes including B12/folate deficiency, blood loss, hemoglobinopathies, and malignancy before attributing anemia solely to CKD 1, 7, 4

The distinction between absolute and functional iron deficiency is therapeutically critical, as functional iron deficiency may respond better to IV iron than oral supplementation due to hepcidin-mediated blockade of intestinal absorption 1, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

New Treatment Approaches for the Anemia of CKD.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2016

Research

Anaemia in CKD-treatment standard.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2024

Research

Practical approach to the diagnosis and treatment of anemia associated with CKD in elderly.

Journal of the American Medical Directors Association, 2006

Guideline

Anemia Management in CKD Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Severe Anemia in CKD Stage 5

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.